<DOC>
	<DOCNO>NCT02894658</DOCNO>
	<brief_summary>The LipiFlow System ( TearScience , Morrisville , NC ) in-office FDA approve treatment meibomian gland dysfunction . It relieve meibomian gland obstruction use heat pulsatile pressure . A recent study observe single treatment LipiFlow system decrease dry eye symptom objective finding meibomian gland dysfunction 1 year . We aim see Lipiflow System beneficial patient Parkinsons disease may difficulty perform normal meibomian gland dysfunction treatment .</brief_summary>
	<brief_title>Lipiflow Versus Warm Compresses Parkinson 's Disease</brief_title>
	<detailed_description>Objectives To determine whether single treatment thermal pulsation relieve dry eye symptom ( primary objective ) improve objective finding meibomian gland dysfunction patient Parkinsons disease . Methods Measures Design - Randomized , control trial - Patient eye randomize either receive single thermal pulsation treatment FDA-approved Lipiflow thermal pulsation system use traditional eyelid hygiene use traditional eyelid hygiene</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients Parkinsons disease dry eye attribute meibomian gland dysfunction Medical diagnosis Parkinsons disease &gt; 18 yearsold Reported dry eye symptom within 3 month baseline examination Standard Patient Evaluation Eye Dryness ( SPEED ) score ≥ 6 baseline visit Evidence meibomian gland obstruction ( base total meibomian gland secretion score ≤ 12 15 gland lower lid ) Willingness stop dry eye medication include antibiotic , nonsteroidal antiinflammatory drug , corticosteroid 2 week prior treatment duration study Active intraocular inflammation Ocular surface abnormality could potentially compromise corneal integrity either eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>